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Abstract 
Medical professionals have a responsibility to act in an ethical manner in everything they do as part 
of their professional life. However, in most cases, it is only when they are carrying out research that 
they have to obtain explicit ethical permission to do their work. This runs the risk that people see 
research ethics as an exercise in getting regulatory clearance, rather than as performing research to 
the highest ethical standards. In this paper I outline some of the ethical issues that should be 
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Key points 
 It is vital that all involved in healthcare undertake research and evaluation of clinical practice 
 Ethical oversight of research protects patients who participate in research 
 Ethical oversight also protects others involved in research, including the researcher 
 Ethical approval must be obtained from research ethics committees (RECs) 
 Different types of research raise different ethical issues 
 When writing a proposal for ethical review, researchers must be aware of the composition 
of the REC 
 It is useful to be aware of the eight factors that the REC will look at when considering a study 
 Different approaches are used for ethical decision-making 
 When comparing treatments, researchers must be in equipoise, genuinely uncertain of 
which is most effective 
 New treatments should always be compared with current best standard therapy 
 Special care must be taken when carrying out research on vulnerable patients 
 It is important to conduct the research ethically 
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 You should published the results, even if they are ‘negative’ 
 The most important factor in whether research is carried out ethically is the researcher 
Importance of carrying out ethical research 
Research throughout the entire healthcare system is essential for the prevention and management 
of disease and the promotion of a healthier society. Research has enabled the advances in medical 
treatment from which patients currently benefit. We need more research to solve not only present 
problems, but also emerging challenges: new infectious diseases, antibiotic resistance and issues 
related to an ageing population. Research (as well as audit and evaluation) should be a duty of all 
healthcare professionals. Indeed, the Secretary of State for Health in England has a statutory duty to 
promote research and use the evidence obtained from research, as outlined in the Health and Social 
Care Act 2012.  
 
Why research needs ethical oversight 
An understanding of research ethics, and of the governance system that oversees research in the UK 
National Health System (NHS), is therefore essential. Systems have developed over the years, often 
in response to adverse incidents where doctors and scientists have, or have been perceived to have, 
mistreated patients in the name of science. Sometimes an investigator has become so focused on 
the science that responsibility for the patient had been forgotten, or there has been unawareness of 
changing values in society.  
Therefore research must take place with appropriate ethical oversight. This protects patients by 
ensuring an independent evaluation of the research. It also protects the researchers, as they can 
demonstrate that their research has external approval, and it can improve research. In addition, it 
protects the various organizations involved in the research (funders, care providers, universities) as 
they can have assurance that their money, facilities or reputation are being used appropriately. The 
whole research enterprise is protected as the public are reassured that projects have been 
scrutinized. it also ensures that the research process has remained aligned to changing public 
opinion. In addition, for some research, it is a legal requirement that ethical approval is in place. 
Publishers and funders usually require proof that approval has been obtained. Carrying out research 
without appropriate approval can have serious repercussions on a career in medicine, including 
removal from the medical register. 
 
Health Research Authority 
I will not describe here the process of obtaining ethical approval in detail. The details change and the 
exact processes depend on the nature of the research and, in some cases, which country in the UK 
the researcher is based in. Every Trust in England (and the equivalent bodies in the devolved 
administrations) has a research and development (R&D) office, and similar arrangements are in 
place for primary care. Talk to someone in R&D office, or its equivalent, at an early stage, and take 
advice from an experienced researcher in your department. There is detailed information on the 
Health Research Authority (HRA) website.1  
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Below, I discuss some of the major issues in ethical review, which will provide a framework for 
understanding what researchers should do when undertaking a research project. One important 
issue is whether your research really is research (Table 1), and the nature of your research project is 
also important (Table2). 
 
Table 1    Is your research research? 
The first question is whether your proposed project is research, clinical audit or service evaluation. 
All three activities are vital in improving healthcare, and the divide can at times seem artificial. 
However, in audit and service evaluation, there are no changes to the treatment or tests that a 
patient undergoes. This distinction is important because, while ethical approval must be obtained 
for research on patients, it is not needed for clinical audit or service evaluation. The HRA provides a 
useful information and decision-making tool for determining whether or not the project is research. 
Further advice is available from the local R&D office or the HRA.. 
The research ethics service for England is run by the HRA, which is responsible for the 67 HRA 
research ethics committees (RECs) in England. The HRA works closely with the devolved 
administrations in Scotland, Wales and Northern Ireland to allow the provision of a single ethical 
opinion across the UK. The HRA also runs HRA Approval, a new process for England in which there is 
an assessment of the governance and legal compliance of research projects. The HRA web pages are 
a useful source of advice and information on research ethics and governance.  
Application to the HRA is made through a single online form (the Integrated Research Application 
System, known as IRAS) that is also used by other groups who regulate research (e.g. the Medicines 
and Healthcare products Regulatory Agency, or MHRA, which approves drugs used in studies).3 
Table 2   Different types of research 
Different types of research can raise different ethical issues. For example, research can involve gene 
therapy or the administration of cells, or can involve testing a new pharmaceutical agent (a Clinical 
Trial of an Investigational Medicinal Product, or CTIMP); it can be a physiological study of healthy 
volunteers, a study involving tissue or DNA from individuals, a questionnaire study or an 
epidemiological study of data. The IRAS application form contains preliminary questions on the sort 
of research being done, so that the remainder of the form is populated with the appropriate 
questions. 
Some projects, not involving patients or human tissue, can be approved by a university rather than 
HRA REC. Certain types of research (e.g. gene therapy, CTIMPs, research involving children or 
participants who may lack capacity) have to go to particular committees with the relevant expertise. 
These RECs are ‘flagged’ for this type of research. On the other hand, for research on human tissue, 
the local tissue bank may have permission to release tissue in defined circumstances. Talk to your 




Research ethics committees 
Research proposals are reviewed by RECs of up to 18 members. At least one third of these are ‘lay’ 
members (i.e. not healthcare professionals or scientists). Their role is to ensure that there is a 
common-sense approach from someone outside the academic/medical ‘bubble’, and also to bring 
their own experience and ability to reason and argue. The rest of the REC are ‘experts’. Some are 
clinicians, scientists or nurses. Others have more specific expertise, such as pharmacy or statistics. 
When filling in the IRAS form, take into account who will be reading it. There may be no one from 
your particular medical discipline on the REC, so make it comprehensible to your audience, and do 
not assume that everyone understands your area of expertise as well as you do.  
 
What RECs consider when assessing a proposal 
RECs usually consider eight specific factors (Table 3) when reviewing a study. In general terms, these 
can be grouped into three main areas: whether the research is valid (is it worth doing, and can it be 
done successfully?), the welfare of the research participants (the burden and risks of doing the 
research) and whether the dignity of the research participants is respected (for example, if they are 
adequately informed and whether their confidentiality is respected?). These cover the main ethical 
issues for any research project.  
For example, the quality of the research is an important ethical issue because if the research has no 
value, or if it is badly designed, the research participants will be wasting their time and be subject to 
unnecessary burden and possibly risk for no benefit to society. In making its decision about these 
issues, the REC may use evidence from other sources, such as independent peer review (e.g. from a 
funding body) to assure them that the research project is well designed and of value. 
Table 3 Eight factors an REC always looks at 
(although it naturally considers other ethical issues that are part of the study) 
1. The social or scientific value; the scientific design and conduct of the study (including the 
involvement of patients, service users and the public, in the design, management and 
undertaking of the research)  
2. Recruitment arrangements and access to health information, and fair selection of research 
participants  
3. Whether there is a favourable risk:benefit ratio; anticipated benefits and/or risks for the 
research participants (present and future)  
4. The care and protection of research participants; respect for the welfare and dignity of 
potential and enrolled research participants  
5. The informed consent process and the adequacy and completeness of information for the 
research participants  
6. Suitability of the applicant and supporting staff  
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7. Independent review  
8. Suitability of supporting information  
 
REC members use different approaches to address these eight factors. These include goal-based 
approaches in which they weigh up the potential benefits and harm of the research and attempt to 
determine whether the benefits outweigh the harms. Members also use duty-based approaches, in 
which the researcher has duties to the participants (e.g. duties not to harm, duties not to deceive, 
etc.). These duties are often similar to those of clinical practice. Finally, many consider the rights of 
research participants (e.g. right to self-determination, right to confidentiality, etc.), and whether the 
research would deny participants their rights.  
These different approaches to ethical reasoning are discussed more fully in other articles in this 
chapter, as they relate more widely to ethical behaviour in medicine.  
 
Differences between research and standard clinical practice 
While the ethical reasoning can be similar between research and clinical practice, there are 
differences in how these work out in the different settings. For example, in clinical practice, there is 
a clear ethical principle that the doctor should act in the best interests of the patient. This  often 
involves evaluating what is the most effective treatment and offering that. However, that is not 
possible in research – the whole point of research is to find out what the most effective treatment is. 
What is frequently sought is ‘equipoise’: at the time the patient is invited onto the trial, it is not 
known whether the research therapy or conventional standard treatment is better.  
Research often involves a comparison between a new therapy (drug or intervention) and the current 
best standard treatment. This can take the form of a randomized controlled trial in which the 
patients are allocated at random between groups being given the new therapy and the conventional 
therapy, usually without knowing which group they are in. It is vital that patients should not be 
knowingly disadvantaged by taking part in the study, and that equipoise is maintained. 
If a treatment is known to be effective for the condition, it is not appropriate to compare the new 
therapy with a placebo control, in which patients receive an inert or ‘dummy’ treatment, as the 
patients in the placebo group would get less good treatment than if they had not been part of the 
study. However, if there is no current effective treatment, it may be appropriate for one group to be 
given placebo alone. Placebo treatment is often used to ‘mask’ from the patients (and indeed the 
researchers) which group they are in; for example, if an experimental agent is administered more 
frequently than the current standard therapy, dummy pills can be used to make up the extra doses, 
so that it is not possible to work out which group the patient is part of.4 
 
Special consideration of vulnerable patients 
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In clinical practice, the doctor’s only concern is the well-being of the patient. However, in research 
the aim is also to add to human knowledge. This therefore gives researchers a particular 
responsibility for vulnerable patients, who may not directly benefit from the research. These include 
children and individuals who do not have capacity to consent for research (e.g. those with learning 
difficulties or dementia). However, there are other groups who are might be under pressure to agree 
to take part in research, such as prisoners and refugees. It is for these reasons that special 
arrangements are put in place to ensure that the rights and well-being of these individuals are 
respected. 
 
And then what? 
Once you have received the ethical approval, and the other approvals needed for the research, what 
happens next? The most important thing is to carry out the research! Follow the approved protocol 
and, if you need to change it, submit the revision to the REC. If there are any problems, let the 
relevant people know. You will also have to submit reports on a regular basis.  
When the research is over, it should be published. The research is only of any public benefit if it is 
published – if no one finds out what has been done, the participants’ time has been wasted, which is 
not ethical. Even negative results can be useful. You should also offer to share the findings of your 
research with those who took part in the study. 
The most important safeguard to ensuring that research is ethically carried out is the researcher, so 
the most important thing is that you conduct your research ethically. This does not just mean 
following the rules, but also treating research participants appropriately, involving them and keeping 
them informed about the research. Carry out the research with integrity – in both the conduct of the 
research and the publication of the results. If there are concerns about the way in which the 





1 Health Research Authority. http://www.hra.nhs.uk/ (accessed 24 Apr 2016). 
2 Health Research Authority. Is it research? http://www.hra.nhs.uk/resources/before-you-
apply/is-it-research/ (accessed 24 Apr 2016). 
3 Integrated Research Application Process. https://www.myresearchproject.org.uk/ (accessed 
24 Apr 2016) 
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There are a large number of guidelines and other information on the conduct of ethical research that 
address particular areas of importance. The most comprehensive and overarching is that issued by 
the Royal College of Physicians, which provides a good overview of the whole area. 
1 Royal College of Physicians. Guidelines on the practice of ethics committees in medical 
research with human participants. https://shop.rcplondon.ac.uk/products/guidelines-on-the-
practice-of-ethics-committees-in-medical-research-with-human-participants?variant=6364998469 




Test yourself  
To test your knowledge based on the article you have just read, please complete the questions 
below.  
Question 1 A researcher proposed a research project in which one group of five patients would 
be given current best therapy that was effective in some patients, and another group of five patients 
would be given a new form of treatment that had been tested in animals but not previously used in 
patients (although it had been given to healthy volunteers to test for safety). An independent 
statistician indicated that the study was underpowered. This study was rejected by the research 
ethics committee.  
What is the most likely reason for this? 
A There is already an effective treatment 
B The study involves too many participants, exposing more patients than needed to the 
experimental therapy 
C The study involves too few participants, thus limiting its ability to produce an answer 
D The drug has been tested in animals 
E It would be unethical to deny some patients the new form of treatment 
 
Answer: C 
Feedback: It is reasonable to undertake research where there is equipoise between the two 
treatments and the current best therapy is not effective for all patients (or has other drawbacks). 
Given that it is not known which treatment is best, it is ethical for the two groups of patients to be 
given different forms of treatment. However, the study must be properly designed and not include 
too many research participants (avoiding exposing more people than needed to the research) or too 
few (which is likely to result in the study failing to produce an outcome). A statistician found that the 
study was underpowered, with too few patients recruited, and this is likely to be the reason for the 
research ethics committee’s rejection. It is usual for new treatments to be tested in animals, as they 
give indications of both safety and efficacy. 
 
Question 2  
A research project was proposed in which women in the final stages of labour would be asked to 
consent to which of two drugs they would be given for pain relief. Both drugs were in routine use. 
The women would be given a comprehensive 22-page document outlining the nature of the research 
project, what would happen to them if they agreed to take part and the risks of the study. It would 
also explain that the research was being paid for by a pharmaceutical company, and that the hospital 
would receive money for every patient recruited. The women would be asked to read the document 
and sign the consent form. This study was not approved by the research ethics committee.  
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What is the most likely reason for this? 
 
A The study is being paid for by a pharmaceutical company 
B The hospital is to receive funding for the study 
C Pregnant women would be being presented with information at the wrong time 
D The drug being given to the women might affect the fetus 
E Research must not be carried out on women in labour as this is an important period for 
them and their families 
 
Answer: C 
Feedback: If treatments during childbirth are to be improved, it is essential that research is carried 
out on women who are pregnant and in childbirth, so this is not likely to be the reason. The research 
ethics committee (REC) would want assurance that safety aspects of doing research on these 
participants have been fully considered. They would also want to know that the study would not 
interfere with the mother’s experience of birth. In addition, it is normal for pharmaceutical 
companies to pay for studies and to reimburse hospitals for their patients’ participation; the REC 
would want to know that this would be done properly. In this case, the REC is likely to consider that 
a woman in the final stages of childbirth would not be in a position to take in 22 pages of 
information and make an informed choice on whether or not she wanted to participate in the 
research. The REC is likely to ask the researchers to think of alternative ways of giving the women 
the necessary information at a time and in a way that allows them to make a decision. 
 
3 A researcher completed their study of a new drug and showed that it was no better (and 
indeed was slightly worse) than the current standard treatment. The researcher decided not to 
publish any papers as this was a negative result that no one would be interested in.  
Which of the following is a reason why even negative results should be published? 
 
A The researcher may in future need a publication for promotion purposes 
B Publication of these data will alert future researchers to the results 
C The researcher can send the publication to the patients who took part in the study to alert 
them to the results 
D It is the law that you should publish the results of all research studies 





Feedback: BAlthough publishing papers can help a researcher’s career, and the funder may (or 
indeed may not) wish the results of the study to be published, it is not a legal requirement for all 
results to be published. However, the Health Research Authority does have expectations for the 
publication and dissemination of research findings. It is also good practice to offer information about 
the study to those who took part in it, although giving all patients a primary research paper may not 
be the best way to do this. The main reason for publishing even negative results is to alert future 
researchers to the results. This has several benefits. One is that others can learn from the results and 
not waste time and resources on work that will not yield benefit. A second is that this reduces the 
risk of publication bias. If only positive studies are published, and negative results ignored, the 
publication record will be biased to the positive results. This can lead to some new forms of therapy 
looking effective when they are not. 
